Ignite Creation Date:
2024-05-06 @ 1:45 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01883362
Status:
COMPLETED
Last Update Posted:
2021-03-17
First Post:
2013-03-25
Brief Title:
Standard of Care - Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-02-06
Start Date Type:
ACTUAL
Primary Completion Date:
2018-04-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-04-30
Completion Date Type:
ACTUAL
First Submit Date:
2013-03-25
First Submit QC Date:
June 19 2013
Study First Post Date:
2013-06-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-03-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-12
Last Update Post Date:
2021-03-17
Last Update Post Date Type:
ACTUAL